Chemical Property of Semustine
Chemical Property:
- Appearance/Colour:Light yellow powder
- Melting Point:64°C (rough estimate)
- Refractive Index:1.51
- PKA:10.89±0.40(Predicted)
- PSA：61.77000
- Density:1.315 g/cm3
- LogP:2.88780
- XLogP3:3.3
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:3
- Exact Mass:247.1087545
- Heavy Atom Count:16
- Complexity:242
- Transport DOT Label:Poison
- Purity/Quality:
-
≥ 98% *data from raw suppliers
Semustine *data from reagent suppliers
Safty Information:
- Pictogram(s):
T
- Hazard Codes:T
- Statements:
45-46-23/24/25-36/37/38
- Safety Statements:
53-22-26-36/37/39-45
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:CC1CCC(CC1)NC(=O)N(CCCl)N=O
- Recent ClinicalTrials:A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
-
Description
In October 2008, scientists of the International Agency for
Research on Cancer reaffirmed the Group 1 classification
‘carcinogenic to humans’ of 20 pharmaceutical agents
including semustine. Me-CCNU [1-(2-chloroethyl)-3-
(4-methylcyclohexyl)-1-nitrosourea] is an alkylating agent of
the nitrosourea group, used alone or in combination with other
chemotherapeutic agents to treat several types of cancers,
including primary and metastatic brain tumors, Lewis lung
tumor, and L1210 leukemia. It has also been used to treat
cancers of the digestive tract, Hodgkin lymphoma, malignant
melanoma, and epidermoid carcinoma of the lung. Doses varied
depending on the type of cancer and body weight of the individual.
The typical oral dose was 125–200 mgm-2 body surface
area, and was repeated every 6 weeks. An alternative regimen
was reported to be 200–225 mg m-2 orally every 6–8 weeks.
Me-CCNU is a bifunctional antineoplastic agent that undergoes
spontaneous chemical decomposition, yielding electrophilic
compounds and ultimately inducing alkylation and carbamoylation
of cellular macromolecules, including DNA and protein.
-
Uses
Me-CCNU is an investigational drug used in chemotherapy to
treat various types of cancers like Hodgkin’s disease, malignant
gliomas, gastrointestinal tract adenocarcinomas, breast carcinomas,
squamous-cell carcinomas, malignant melanoma, and
epidermoid carcinoma of the lung. It is an antineoplastic agent
that functions as an alkylating agent. An emerging trend in this
arena has been to design hybrid steroid compounds of anticancer
agents, because they presumably produce less toxicity,
significantly lower than the cytotoxic components alone, and
increase anticancer activity of alkylating esters. Commonly used in pharmacological studies involving: ? ;Nutrient-sensitized screening for drugs that shift the energy metabolism from mitchondrial respiration to glycolysis1? ;CEOP regimen with semustine used as induction chemotherapy in patients with lymphoma2? ;Investigations into its use for chemotherapy3,4 antihyperlipidemic
